Abstract:Background and aims: It is uncertain what impact increasing voluntary folate fortification may be having on the statistical power of randomized trials testing the homocysteine hypothesis of atherothrombosis. The objective of this study was to determine whether there has been a change in folate status between 1998 and 2002 in stroke patients randomized into the VITAmins TO Prevent Stroke (VITATOPS) Study at a single center in Perth, Australia, and what impact this may have had on the magnitude of the homocysteine-lowering effect achieved over time with folic acid-based multivitamin therapy. Methods: We conducted a randomized, double-blind, placebo-controlled study involving 285 patients with stroke or transient ischemic attack who were recruited between 1998 and 2002 and randomized to long-term folic acid 2.0 mg/day, pyridoxine 25 mg/day and cobalamin 0.5 mg/day (active VITATOPS medication) or placebo. Fasting plasma total homocysteine, red cell folate, serum cobalamin and serum pyridoxine levels were measured at baseline and 6 months, and the change in blood levels over 4 time quartiles and differences in levels between the two randomized treatments were examined. Results: Between 1998 and 2002, there was a significant rise in baseline mean red cell folate levels over 4 time quartiles among the entire stroke cohort (723.3, 780.1, 922.6 and 1,023.7 nmol/l in the first, second, third and fourth quartiles, respectively; p < 0.0001), but this was not associated with a spontaneous reduction in mean baseline total homocysteine levels during the same time period (12.7, 14.3, 12.1 and 12.8 micromol/l in the first, second, third and fourth quartiles, respectively; p = 0.55). The homocysteine-lowering effect of the active VITATOPS trial medication at 6 months after randomization also did not change significantly between 1998 and 2002 (difference between randomized groups: -4.1, -4.1, -3.1 and -3.6 micromol/l in the first, second, third and fourth quartiles, respectively; p = 0.56). Conclusions: The homocysteine-lowering effect of the active VITATOPS trial medication has not attenuated significantly in the past 5 years despite increasing voluntary fortification of foods with folic acid as reflected by a progressive rise in baseline folate status. These data suggest that in the continuing absence of a program of mandatory folate fortification of food in populations served by centers participating in the VITATOPS trial, the study will remain adequately powered to test the homocysteine-lowering hypothesis for which it was designed.

Treatment of Hyperhomocysteinemia with Folic Acid: Effects on Homocysteine Levels, Coagulation Status, and Oxidative Stress Markers

[Effect of Low-Dose Folate Treatment on Plasma Homocystyeine and Chemokine Levels in Patients with Hyperhomocysteinemia].

A Meta-Analysis of Folic Acid in Combination with Anti-Hypertension Drugs in Patients with Hypertension and Hyperhomocysteinemia

Clinical Efficacy of Folic Acid in Treating Senile Hypertension and Influence on Plasma Homocysteine Level and Vascular Endothelial Function

[Homocysteine, Folate Therapy and Outcome in Hemodialysis: Results from a Prospective Study].

Folic Acid Supplementation in Patients with Elevated Homocysteine Levels

Effect of Long-Term Low-Dose Folic Acid Supplementation on Degree of Total Homocysteine-Lowering: Major Effect Modifiers

The Roles of Aerobic Exercise and Folate Supplementation in Hyperhomocysteinemia-Accelerated Atherosclerosis.

Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension: A double-blinded, randomized clinical cohort study

Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population

Folic Acid Reverses Hyper-Responsiveness of LPS-induced Chemokine Secretion from Monocytes in Patients with Hyperhomocysteinemia

Effect of folic acid on plasma homocysteine levels and cognitive function in elderly patients with cerebral infarction and hypertension

Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials

Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels

Polymorphisms and the Homocysteine Lowering Efficacy of Different Doses of Folic Acid in Hypertensives Chinese Adults

Folic Acid Treatment for Patients with Vascular Cognitive Impairment: A Systematic Review and Meta-Analysis

Effect of folic acid in women with and without insulin resistance who have hyperhomocysteinemic polycystic ovary syndrome

Homocysteine-lowering Therapy with Folic Acid is Effective in Cardiovascular Disease Prevention in Patients with Kidney Disease: a Meta-Analysis of Randomized Controlled Trials.

[Hyperhomocysteinemia in patients with cardiovascular disease]

Influencing Factors of Hyperhomocysteinemia and Effect of High Dose Folic Acid Treatment in Maintenance Hemodialysis Patients

MTHFR Gene and Serum Folate Interaction on Serum Homocysteine Lowering: Prospect for Precision Folic Acid Treatment.